Transgene Biotek Limited
TRABI
Rank in Stocks
#32253
Transgene Biotek Ltd. is a biotechnology enterprise focused on the development... Transgene Biotek Ltd. is a biotechnology enterprise focused on the development and commercialization of diagnostic kits. The company is also active in the manufacturing and oral formulation of diverse proteins through its distinctive TrabiORAL technology. Its array of products includes TrabiDHA, Tacrolimus, and Orlistat. K. Koteswara Rao established the firm in 1991, and its primary operations are based in Hyderabad, India.
Share Price
$0.02682362
Last synced: 2026-11-09
Market Cap
$1.79M
Change (1 day)
0.15%
Change (1 year)
-38.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Transgene Biotek Limited (TRABI)
Category
Healthcare
Operating Margin for Transgene Biotek Limited (TRABI)
Operating Margin as of November 2026 TTM: -294.77%
According to Transgene Biotek Limited's latest financial reports, its current operating margin (TTM) is -294.77%. At the end of 2025 the company had an operating margin of -466.63%.
Operating Margin history for Transgene Biotek Limited from 2006 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -294.77% | -36.83% |
| 2025 | -466.63% | 54.62% |
| 2024 | -301.79% | -97.23% |
| 2023 | -10,897.07% | -9.05% |
| 2022 | -11,981.96% | 94.68% |
| 2021 | -6,154.64% | -97.96% |
| 2020 | -300,960.40% | 1,928.26% |
| 2019 | -14,838.33% | 46.27% |
| 2018 | -10,144.69% | -65.05% |
| 2017 | -29,028.03% | 144.67% |
| 2016 | -11,864.37% | 95.16% |
| 2015 | -6,079.27% | -55.29% |
| 2014 | -13,597.71% | 100,326.22% |
| 2013 | -13.54% | -120.67% |
| 2012 | 65.49% | -174.81% |
| 2011 | -87.54% | -367.22% |
| 2010 | 32.76% | -6.69% |
| 2009 | 35.11% | -10.52% |
| 2008 | 39.24% | -41.89% |
| 2007 | 67.53% | -1,495.25% |
| 2006 | -4.84% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.13% |
US
|
|
| -149.01% | -99.49% |
US
|
|
| 25.57% | -100.09% |
AU
|
|
| 31.23% | -100.11% |
BE
|
|
| 29.35% | -100.10% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Transgene Biotek Limited's operating margin
What is Transgene Biotek Limited's operating margin?
Transgene Biotek Limited's operating margin is -294.77%, as of Nov 2026.
What was Transgene Biotek Limited's operating margin in 2025?
In 2025, Transgene Biotek Limited's operating margin was -466.63%, compared with -301.79% in 2024.
How has Transgene Biotek Limited's operating margin changed since 2020?
From 2020 to 2025, Transgene Biotek Limited's operating margin was highest in 2024 (-301.79%) and lowest in 2020 (-300,960.40%).
How does Transgene Biotek Limited's operating margin compare with similar companies?
Transgene Biotek Limited's operating margin (-294.77%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.